Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II nivolumab in relapsed/refractory ALK-positive anaplastic large cell lymphoma
2018-001447-31Phase 2Active
- Sponsor
- Gustave Roussy
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab in anaplastic large cell lymphoma (ALCL) (2 cohorts), sponsored by Gustave Roussy. Primary endpoint: Best objective response rate. Started Aug 2018; status: active.
02
Drugs
03
Conditions
anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on 2018-001447-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001447-31.